The Riceen Letter was sent out early because Riceen was taking a trip to France to have a meeting with some of his followers. He did say he was very proud of his predictions that week and it was 92% right. That was pretty good in his book. He wrote that on Thursday there will be a stock correction with the Dow downd 264 points. But, he also said that Friday will be a buying opportunity. And the market will be up 124 points. The Dow will be down for the week over 100 points.
He writes that SRPT will be higher by Friday after going down on Thursday $1.43.
Monday. Closes at $37.42
Tuesday Closes at $38.43
Wendesday closes at $36.79
Thursday. Closes at $35.33
Friday. Closes at $37.79
Riceen also told his followers that SRPT will be in the 40's by the end of May.
Todd is an epitome of 'incompetence'. His judgment is bordering with dogma - a mediocrity that is so common to MF.
Derepression of DUX4 in skeletal muscle has emerged as a likely cause of pathology in facioscapulohumeral muscular dystrophy (FSHD). Here we report on the use of antisense phosphorodiamidate morpholino oligonucleotides to suppress DUX4 expression and function in FSHD myotubes and xenografts. The most effective was phosphorodiamidate morpholino oligonucleotide FM10, which targets the polyadenylation signal of DUX4. FM10 had no significant cell toxicity, and RNA-seq analyses of FSHD and control myotubes revealed that FM10 down-regulated many transcriptional targets of DUX4, without overt off-target effects. Electroporation of FM10 into FSHD patient muscle xenografts in mice also down-regulated DUX4 and DUX4 targets. These findings demonstrate the potential of antisense phosphorodiamidate morpholino oligonucleotides as an FSHD therapeutic option.Molecular Therapy (2016); doi:10.1038/mt.2016.111.
PMID: 27378237 DOI: 10.1038/mt.2016.111
Purpose, of course. Every MF article has no bottom line - all of them infest the doubt. It's pseudo-knowledgeable business that fools naive investors,
A true test will come shortly when the FDA decides on Sarepta Therapeutics' (NASDAQ:SRPT) DMD drug eteplirsen. The agency was scheduled to make a decision last month, but delayed that decision indefinitely, and subsequently asked Sarepta Therapeutics for additional data.
The original data package was less than perfect, mainly due to a small number of patients in the phase 2 trial that was never really designed as a pivotal trial. The FDA's committee of outside advisors recommended against approving the drug, but the fact that the FDA didn't issue an outright rejection hints at the FDA's willingness to be flexible. Sarepta Therapeutics has already started a phase 3 trial, and has plans for an additional trial that might make the FDA willing to issue an accelerated approval if the new data satisfies regulators.
If the FDA approves eteplirsen, Sarepta's shares will soar. More importantly, it'll give investors confidence in the overall ability of biotech companies to get drugs past regulators.
Sarepta Therapeutics (SRPT) has maintained “radio silence…as it prepares to submit data to FDA” but that hasn’t stopped Wedbush analyst Heather Behanna from weighing in on the potential for an approval of its treatment for Duchenne muscular dystrophy:
In line with its press release on June 6th, where submission of dystrophin data from 13 boys from PROMOVI was expected “over the coming weeks”, we anticipate data submission this month. The company is now in a quiet period, which we believe may continue until an FDA decision on approval. In our view, eteplirsen has a good chance of accelerated approval if it demonstrates a drug-induced increase of dystrophin from baseline. We remind investors that a key sticking point with FDA is whether or not dystrophin quantified at 180 weeks were driven by eteplirsen or present at baseline. As a reminder, we have seen baseline dystrophin of six boys from PROMOVI – half had no dystrophin at baseline – in our view, making a significant increase from baseline achievable.
Changes to the pivotal study of SRP-4045 and -4053 (ESSENCE) suggest to us it could be confirmatory for eteplirsen. Sarepta was waiting to begin its ESSENCE study to incorporate agency feedback after the advisory panel; it is set to begin next month. As a reminder, FDA has stated that a placebo controlled study in boys with other exons could be confirmatory for eteplirsen. Sarepta has amended the protocol for ESSENCE in ways that we believe improves its chance for success. The key change, in our view, is a shift of primary endpoint (6MWT) to 96 weeks from 48 with an independently adjudicated interim analysis when 75 boys are through 48 weeks. In our view, this design manages the desire for all boys to be on drug with the need for a robust placebo controlled study run long enough to demonstrate a drug effect of exon skipping to support full FDA approval.
Shares of Sarepta Therapeutics have gained 2.1% to $17.78 at 3:45 p.m. today.